Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Jun 12, 2024 10:47am
98 Views
Post# 36084740

RE:RE:RE:Multiple thoughts.

RE:RE:RE:Multiple thoughts.I don't want to be CEO... thanks for the suggestion but I'm quite content in my role thanks...

My point is simply that Matt failed to reduce time to market, by running all the additional trials since the SPA was granted. They didn't HAVE to do those... FDA gave recommendations sure (and we only have ONCY's word on that).

But why would Matt claim that the Aware-1 trial data was all that was needed for Roche to pull the trigger...  they haven't... He ran Bracelet-1 not because he needed to, but to generate competive bidding - that failed spectacularly, and then we find out after the event that the triplet combo could be expected to be worse... that's a BIG fail.

I just want the record straight on his performance... I'm not saying I would do better, but I am not in his role, nor do I have the inside info he is privvy to.

Whilst we deliberate, the stocks I bought to replace 1/2 the ONCY position I once had are flying. This is just too risky until Ph III funding question is answered.


<< Previous
Bullboard Posts
Next >>